What NeuPharma does

Suzhou NeuPharma Co., Ltd. (苏州润新生物科技有限公司), branded as NeuPharma, is a privately held clinical-stage biopharmaceutical company founded in 2019 in Suzhou BioBay, China, by returnee pharmaceutical industry professionals. The company develops innovative small-molecule anti-cancer therapeutics through a proprietary targeted drug discovery platform and currently operates four clinical-stage candidates: RX108, a Na+/K+-ATPase signal-transduction inhibitor in Phase II across glioblastoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma, with a Phase I oral tablet formulation (RX108-A) initiated in February 2025; RX208 (HLX208), a selective BRAF V600E inhibitor that received China NMPA Breakthrough Therapy Designation in April 2023 for BRAF V600E-mutated adult LCH/ECD and is licensed to Henlius for Greater China; RX518 (CK-101), a third-generation EGFR-TKI in Phase III for EGFR-mutated non-small cell lung cancer under collaboration with U.S.-based Checkpoint Therapeutics; and RX608, a dual BRAF V600/VEGFR inhibitor in Phase I as a Category 1 innovative drug. NeuPharma is led by President and CEO Dr. Qian Xiangping (钱向平).

The company's underlying technology centers on medicinal chemistry differentiated by novel mechanisms of action — most notably sodium-potassium ATPase inhibition for cell-cycle arrest and autophagy, and dual kinase blockade combining tumor-growth inhibition with anti-angiogenesis — supported by global intellectual property protection across multiple chemical scaffolds. NeuPharma's business model is pre-commercial and asset-partnership-driven: rather than building in-house sales infrastructure, the company out-licenses regional rights to industrial partners (Henlius for Greater China on RX208; Checkpoint Therapeutics for global RX518 development) and collaborates with academic institutions including Nanjing University, Shanghai Jiao Tong University, and Soochow University for upstream research. Revenue, where any exists, derives from upfront license payments, development and sales milestone fees, and royalties, with the disclosed Henlius agreement representing CNY 97.5 million upfront plus up to CNY 1.08 billion in potential milestones plus tiered royalties. No pricing model, customer base, or commercial product exists at present.

Name

NeuPharma

Legal name

Suzhou NeuPharma Co., Ltd.

Website

http://neupharma.com/

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

NeuPharma is a privately held, Suzhou-based clinical-stage biopharmaceutical company developing four proprietary small-molecule anti-cancer drug candidates (RX108, RX208, RX518, RX608) across solid-tumor and rare-disease oncology indications, partnering regionally with Henlius and Checkpoint Therapeutics for development and commercialization.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Oncology drug development
• Small molecule therapeutics
• Targeted cancer therapy
• Clinical stage biopharmaceuticals
• Novel anti-cancer drugs

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

Core offering

NeuPharma is a clinical-stage biopharmaceutical company that discovers and develops proprietary small-molecule anti-cancer drug candidates through a targeted drug discovery platform. Its pipeline comprises multiple novel-mechanism oncology assets (RX108 Na+/K+-ATPase inhibitor, RX208 BRAF V600E inhibitor, RX518 third-generation EGFR-TKI, and RX608 dual BRAF/VEGFR inhibitor) currently in Phase I–III clinical trials across solid tumors and hematological malignancies. The company monetizes pipeline assets via regional out-licensing and co-development partnerships with larger pharmaceutical companies rather than through direct commercialization.

Product overview

NeuPharma is a clinical-stage biopharmaceutical company developing a portfolio of innovative small-molecule anti-cancer drugs. The pipeline includes: RX108 (Na+/K+-ATPase inhibitor in Phase II for multiple solid tumors including glioblastoma and HCC, also available as oral RX108-A tablets in Phase I); RX208 (BRAF V600E inhibitor licensed to Henlius for Greater China, in Phase II for LCH/ECD with breakthrough therapy designation); RX518 (third-generation EGFR-TKI in Phase III for NSCLC, developed with Checkpoint Therapeutics); and RX608 (dual BRAF/VEGFR inhibitor in Phase I). The company operates a proprietary targeted drug discovery platform focused on oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• RX108 Novel small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with a multi-target anti-tumor mechanism (cell-cycle arrest, apoptosis, autophagy). Being developed for solid tumors including glioblastoma, hepatocellular carcinoma, head and neck cancer, and brain metastasis; currently in Phase II clinical trials.
• RX108-A Tablets Oral tablet formulation of RX108 (Na+/K+-ATPase inhibitor) for treatment of locally advanced or metastatic solid tumors, with clinical focus on high-grade glioma and brain metastasis. Currently in Phase I clinical trials in China.
• RX208 (HLX208) Selective small-molecule BRAF V600E kinase inhibitor with proprietary novel chemical structure, exhibiting high bioavailability and anti-tumor efficacy. Being developed for BRAF V600E-mutant colorectal cancer, melanoma, and rare indications Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD). Licensed to Henlius for Greater China development and commercialization.
• RX518 (CK-101) Novel, potent, irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-sensitive mutations (exon 21 L858R and exon 19 deletion) and the EGFR T790M resistance mutation, with weak inhibition of wild-type EGFR. Developed for EGFR-mutant non-small cell lung cancer in collaboration with Checkpoint Therapeutics; in Phase III in China.
• RX608 Dual-mechanism small-molecule inhibitor that simultaneously inhibits BRAF V600 kinase activity and VEGFR kinase activity, combining tumor growth inhibition with anti-angiogenesis. Targeted at advanced solid tumors with BRAF or RAS mutations. Currently in Phase I clinical trials in China.

Quantifiable outcome

• Global market potential for corticorelin exceeds USD 1 billion annually with ~500,000 eligible patients worldwide
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Neupharma Co., Ltd.coreStrategic or Co-development Partner · 11 March 2026Exclusive licensing agreement for corticorelin (C-PTBE-01) development and commercialization in Japan. Neupharma received exclusive rights to develop and commercialize the therapy for peritumoral brain edema. Curatis to receive upfront and milestone payments up to CHF 83.5 million plus royalties up to 20% on future Japanese sales. Neupharma planning to meet Japanese regulators (PMDA) in summer 2026 to discuss pivotal trial requirements.
• Henlius (复宏汉霖)coreStrategic or Co-development Partner · 29 March 2021Exclusive licensing agreement granting Henlius rights to research, develop, produce, commercialize and sublicense RX208 (HLX208), a BRAF V600E inhibitor, in China (including Hong Kong, Macau and Taiwan). NeuPharma received CNY 97.5 million upfront payment and up to CNY 1.08 billion in development, registration and sales milestone payments plus sales royalties. Henlius is conducting Phase 2 clinical trial of RX208 for treatment of adult LCH and ECD with BRAF V600E mutation in China.
• Checkpoint TherapeuticscoreStrategic or Co-development PartnerCollaboration on development of RX518 (CK-101), a third-generation EGFR-TKI inhibitor. Clinical trials being conducted in USA, Australia and multiple countries. RX518 in Phase I/II trial under collaboration with Checkpoint Therapeutics.
• Nanjing UniversityminorOthersAcademic partnership for research and development activities.
• Shanghai Jiao Tong UniversityminorOthersAcademic partnership for research and development activities.
• Soochow University (苏州大学)minorOthersAcademic partnership for research and development activities.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Mirati Therapeutics: Precision oncology company developing targeted small-molecule therapies including KRAS and BRAF pathway inhibitors; comparable in targeting specific oncogenic mutations with novel chemistry.
• BeiGene: Large Chinese-founded oncology biotech with global commercial footprint; comparable in that it develops innovative small-molecule and biologic oncology drugs, but operates at substantially greater scale with commercialized products.
• Junshi Biosciences: Innovative Chinese biopharma with oncology pipeline including small-molecule and biologic candidates; relevant comparator for Suzhou BioBay ecosystem companies and Chinese NMPA regulatory navigation.
• Innovent Biologics: China-based oncology-focused biopharma with both small-molecule and biologic pipeline; relevant comparator for Chinese oncology pipeline development, licensing strategy, and multi-asset approach.
• Genentech / Roche Oncology: Global oncology incumbent with vemurafenib (BRAF) and other targeted therapies; represents the competitive landscape and validation point for the BRAF V600E and EGFR spaces NeuPharma operates in.

Direct peers

• Hutchmed (Chi-Med): Innovative Chinese oncology biopharma with proprietary small-molecule discovery platform; comparable business model of out-licensed and self-developed assets (e.g., surufatinib, savolitinib) serving similar global markets as NeuPharma.
• Checkpoint Therapeutics: NeuPharma's development partner for RX518 (CK-101); small US oncology biotech co-developing a third-generation EGFR-TKI in NSCLC, providing a direct peer in trial execution and out-licensing economics.
• Henlius (Shanghai Fosun): NeuPharma's exclusive licensee for RX208 in Greater China; comparable Chinese oncology-focused biopharma with active clinical pipeline and cross-border deal-making experience.
• CStone Pharmaceuticals: Clinical-stage Chinese oncology company developing innovative small-molecule and biologic therapies; comparable pipeline-stage business model with similar dependence on out-licensing deals for commercialization.

Others

• Plexxikon (Daiichi Sankyo): Small-molecule kinase inhibitor discovery company (now part of Daiichi Sankyo) that pioneered vemurafenib (BRAF V600E); relevant historical comparator for novel BRAF V600E chemistry targeting similar oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/suzhou-neupharma-co.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuPharma